A Phase III, Randomized, Double Blind, Active-Controlled, Prospective, Comparative, Parallel Group, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Empagliflozin, Sitagliptin and Metformin Hydrochloride Extended Release Tablets Versus Fixed Dose Combination of Dapagliflozin, Sitagliptin and Metformin Hydrochloride Extended Release Tablets in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy. - NIL
A Phase III, Randomized, Open Label, Active-Controlled, Prospective, Parallel Group, Comparative, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Dapagliflozin and Sacubitril/Valsartan Tablets Versus Concomitant Administration of Dapagliflozin and Sacubitril/Valsartan Tablets in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). - NIL
A Phase III, Randomized, Double Blind, Active-Controlled, Prospective, Comparative, Parallel Group, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Dapagliflozin plus Telmisartan Tablets Versus Concomitant Administration of Dapagliflozin Tablets and Telmisartan Tablets in Patients with Chronic Kidney Disease. - NIL
100 Clinical Results associated with Exemed Pharmaceuticals
0 Patents (Medical) associated with Exemed Pharmaceuticals
100 Deals associated with Exemed Pharmaceuticals
100 Translational Medicine associated with Exemed Pharmaceuticals